Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2014

01-02-2014 | ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgement

Published in: Cancer Immunology, Immunotherapy | Issue 2/2014

Login to get access

Excerpt

The Editors-in-Chief thank the following reviewers and our Editorial Board for evaluating manuscripts submitted to Cancer Immunology, Immunotherapy in 2013. We are committed to the publication of research that advances the field of tumor immunology and immunotherapy and rely on our many reviewers to ensure that papers accepted by the journal are of high quality and have significant scientific merit. We very much appreciate the voluntary unremunerated provision of their expertise and time by our reviewers, and recognize that their constructive comments and recommendations are essential contributions promoting the overall quality of CII and the scientific record. …
Metadata
Title
Acknowledgement
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 2/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1517-z

Other articles of this Issue 2/2014

Cancer Immunology, Immunotherapy 2/2014 Go to the issue

Meeting Report

Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany

Original Article

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

Original Article

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

Review

Neuropilin 1: function and therapeutic potential in cancer

Original Article

HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers

Original Article

Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits